Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region

Rheumatic Heart Disease Clinical Trial

Official title:

Genome-wide Association Study of Susceptibility to Rheumatic Heart Disease in Fiji and New Caledonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02188862
• Other study ID #: PACIFICRHDGEN
• Status: Completed
• Phase: N/A
• First received: July 10, 2014
• Last updated: July 14, 2014
• Start date: September 2012
• Est. completion date: December 2013

Study information

• Verified date: July 2014
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics CommitteeFrance: Ethics CommitteeFiji: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate whether there are genetic differences between patients with rheumatic heart disease and members of the general population.

Description:

The investigators will micro-array genotype approximately 300,000 single nucleotide polymorphisms (SNP) using DNA samples from patients with rheumatic heart disease (cases) from New Caledonia and Fiji, and members of the general population (controls) from New Caledonia, Vanuatu and Fiji. The investigators will perform standard quality control checks on the SNP data using measures such as call rate, heterozygosity, duplication and relatedness, and exclude variants on the basis of deviation from Hardy-Weinberg equilibrium and minor allele frequency. We will also impute variants not present on the micro-array with reference to the latest release of 1000 Genomes data and whole-genome sequence data from sixty Melanesian individuals from New Caledonia from the phenotypic extremes in this study.

The investigators will conduct a discovery analysis in using a genome-wide association study approach focusing on Oceanic cases and controls from the Francophone nations of New Caledonia and Vanuatu. This analysis will be corrected for bias due to population stratification using the Linear Mixed Model (LMM) and consider additive, dominant and recessive genetic models. The investigators will then perform LMM association testing for variants with P-value in the discovery analysis less than 1x10^-5 in Oceanic cases and controls from Fiji and combine the association statistics by fixed-effects meta-analysis. The investigators will consider variants with significant effects in the same direction in discovery and replication analyses with combined P-value less than 1x10^-8 to have replicated. Unless there is clear evidence that associated variants are specific to Oceanic populations, further replication analyses for associated variants in cases and controls of Indian Descent from Fiji, as well as individuals of other and admixed ethnicities from both Fiji and New Caledonia.

Recruitment completed in December 2013. After receipt of funding from the British Heart Foundation, genotyping and analysis will begin in July 2014.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2372
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 5 Years and older

Eligibility

1. Cases

1. Inclusion Criteria:

• Diagnosis of rheumatic heart disease based on one of:

• World Heart Federation definite echocardiographic criteria

• World Heart Federation borderline echocardiographic criteria and history of acute rheumatic fever

• Mitral stenosis with valve area less than 2.0 cm2

• Previous surgery for rheumatic heart disease

2. Exclusion Criteria:

• Age less than five years

• Inability to give consent

2. New Controls

1. Inclusion criteria:

• Healthy individual living in a community where cases were identified

2. Exclusion Criteria:

• Past medical history or systems suggestive of rheumatic heart disease, acute rheumatic fever or other valvular heart disease

• Age less than five years

• Inability to give consent

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Disease Susceptibility
• Heart Diseases
• Mitral Stenosis
• Mitral Valve Stenosis
• Rheumatic Diseases
• Rheumatic Heart Disease

Locations

Country	Name	City	State
Fiji	Colonial War Memorial Hospital	Suva
New Caledonia	Centre Hospitalier Territorial de Nouvelle Caledonie	Noumea
United Kingdom	Wellcome Trust Centre for Human Genetics, University of Oxford	Oxford

Sponsors (7)

Lead Sponsor	Collaborator
University of Oxford	Centre Hospitalier Territorial de Nouvelle Calédonie, Fiji National University, Institut National de la Santé Et de la Recherche Médicale, France, Institut Necker Enfants Malades, Ministry of Health, Fiji, University of Melbourne

Countries where clinical trial is conducted

Fiji,  New Caledonia,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rheumatic heart disease diagnosis	Diagnosis of rheumatic heart disease as layout in enrolment criteria for cases.	At enrolment	No
Secondary	Mitral stenosis diagnosis	History or echocardiographic diagnosis of mitral stenosis	At enrolment	No